215 related articles for article (PubMed ID: 31201937)
1. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions.
Park HJ; Yun J; Kang DY; Park JW; Koh YI; Kim S; Kim SH; Nam YH; Jeong YY; Kim CW; Park HK; Kim SH; Kang HR; Jung JW;
J Allergy Clin Immunol Pract; 2019; 7(8):2739-2749.e3. PubMed ID: 31201937
[TBL] [Abstract][Full Text] [Related]
2. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
3. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
Chung WH; Chang WC; Stocker SL; Juo CG; Graham GG; Lee MH; Williams KM; Tian YC; Juan KC; Jan Wu YJ; Yang CH; Chang CJ; Lin YJ; Day RO; Hung SI
Ann Rheum Dis; 2015 Dec; 74(12):2157-64. PubMed ID: 25115449
[TBL] [Abstract][Full Text] [Related]
4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling in allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
van Nguyen D; Chu HC; Vidal C; Anderson J; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Fulton RB; van Nunen S; Fernando S
Pharmacogenomics; 2020 Sep; 21(14):985-994. PubMed ID: 32896208
[No Abstract] [Full Text] [Related]
6. Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea.
Lee HS; Ueta M; Kim MK; Seo KY; Sotozono C; Kinoshita S; Yoon KC
Cornea; 2016 Feb; 35(2):199-204. PubMed ID: 26655481
[TBL] [Abstract][Full Text] [Related]
7. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
van Nguyen D; Chu HC; Vidal C; Fulton RB; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Chu HH; Thanh Thuc HT; Minh Le HT; van Nunen S; Anderson J; Fernando SL
Pharmacogenomics; 2021 Jan; 22(1):1-12. PubMed ID: 33356553
[No Abstract] [Full Text] [Related]
8.
Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
[TBL] [Abstract][Full Text] [Related]
9. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
10. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
[TBL] [Abstract][Full Text] [Related]
11. A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea.
Kang DY; Yun J; Lee SY; Koh YI; Sim DW; Kim S; Nam YH; Park JW; Kim SH; Ye YM; Park HK; Kim MH; Jee YK; Jung JW; Yang MS; Kim SH; Lee JK; Kim CW; Hur GY; Kim MY; Park SJ; Kwon YE; Choi JH; Kim JH; Kim SH; La HO; Kang MG; Park CS; Lee SM; Jeong YY; Kim HK; Jin HJ; Jeong JW; Lee J; Lee YW; Lee SE; Kim MS; Kang HR;
J Allergy Clin Immunol Pract; 2021 Feb; 9(2):929-936.e7. PubMed ID: 32961314
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.
Sato T; Cheng CL; Park HW; Kao Yang YH; Yang MS; Fujita M; Kumagai Y; Tohkin M; Saito Y; Sai K
Clin Transl Sci; 2021 May; 14(3):1002-1014. PubMed ID: 33382928
[TBL] [Abstract][Full Text] [Related]
13. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.
Ng CY; Yeh YT; Wang CW; Hung SI; Yang CH; Chang YC; Chang WC; Lin YJ; Chang CJ; Su SC; Fan WL; Chen DY; Wu YJ; Tian YC; Hui RC; Chung WH;
J Invest Dermatol; 2016 Jul; 136(7):1373-1381. PubMed ID: 26996548
[TBL] [Abstract][Full Text] [Related]
14. HLA-B*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia.
Low DE; Nurul-Aain AF; Tan WC; Tang JJ; Bakhtiar MF; Murad S; Chang CC; Too CL; Tang MM
Pharmacogenet Genomics; 2020 Sep; 30(7):153-160. PubMed ID: 32433341
[TBL] [Abstract][Full Text] [Related]
15. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population.
Saksit N; Tassaneeyakul W; Nakkam N; Konyoung P; Khunarkornsiri U; Chumworathayi P; Sukasem C; Suttisai S; Piriyachananusorn N; Tiwong P; Chaiyakunapruk N; Sawanyawisuth K; Rerkpattanapipat T; Tassaneeyakul W
Pharmacogenet Genomics; 2017 Jul; 27(7):255-263. PubMed ID: 28509689
[TBL] [Abstract][Full Text] [Related]
18. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
[TBL] [Abstract][Full Text] [Related]
19. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
